- Home
- TVGN vs TIL Comparison
TVGN vs TIL Comparison
Compare TVGN & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- TIL
- Stock Information
- Founded
- TVGN 2020
- TIL 2018
- Country
- TVGN United States
- TIL United States
- Employees
- TVGN N/A
- TIL N/A
- Industry
- TVGN Blank Checks
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- TIL Health Care
- Exchange
- TVGN Nasdaq
- TIL Nasdaq
- Market Cap
- TVGN 179.0M
- TIL 177.1M
- IPO Year
- TVGN N/A
- TIL 2021
- Fundamental
- Price
- TVGN $0.87
- TIL $31.50
- Analyst Decision
- TVGN Strong Buy
- TIL Buy
- Analyst Count
- TVGN 1
- TIL 6
- Target Price
- TVGN $10.00
- TIL $120.50
- AVG Volume (30 Days)
- TVGN 663.2K
- TIL 109.0K
- Earning Date
- TVGN 08-14-2025
- TIL 08-13-2025
- Dividend Yield
- TVGN N/A
- TIL N/A
- EPS Growth
- TVGN N/A
- TIL N/A
- EPS
- TVGN N/A
- TIL N/A
- Revenue
- TVGN N/A
- TIL N/A
- Revenue This Year
- TVGN N/A
- TIL N/A
- Revenue Next Year
- TVGN N/A
- TIL N/A
- P/E Ratio
- TVGN N/A
- TIL N/A
- Revenue Growth
- TVGN N/A
- TIL N/A
- 52 Week Low
- TVGN $0.26
- TIL $10.80
- 52 Week High
- TVGN $3.09
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- TVGN 33.67
- TIL 61.57
- Support Level
- TVGN $0.85
- TIL $26.69
- Resistance Level
- TVGN $0.95
- TIL $28.85
- Average True Range (ATR)
- TVGN 0.05
- TIL 2.16
- MACD
- TVGN 0.00
- TIL 0.43
- Stochastic Oscillator
- TVGN 10.63
- TIL 76.70
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.